XENE
Xenon Pharmaceuticals Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow -14.4% ·
net new positions -9.1%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 114 | +7 | 55.64M | $3.35B | +11 | −4 |
| Q1 2026 | 110 | +12 | 59.13M | $3.41B | +18 | −6 |
| Q4 2025 | 96 | 0 | 51.65M | $2.31B | +1 | −1 |
| Q3 2025 | 17 | 0 | 29.02M | $1.17B | — | — |
| Q2 2025 | 14 | -1 | 23.81M | $745.12M | +1 | −2 |
| Q1 2025 | 12 | +1 | 10.74M | $360.22M | +1 | — |
| Q4 2024 | 11 | -1 | 10.24M | $401.45M | — | −1 |
| Q3 2024 | 11 | 0 | 11.68M | $459.86M | — | — |
| Q2 2024 | 11 | — | 11.68M | $455.36M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.78M | -1.7% | $148.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.78M | -1.7% | $148.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.78M | -1.7% | $148.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.78M | -1.7% | $148.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.78M | -1.7% | $148.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Capital World Investors ✦ | 2.29M | -14.4% | $89.95M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 1.86M | -10.6% | $73.05M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 899.72K | -24.7% | $35.27M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Millennium Management ✦ | 346.04K | +65.5% | $13.56M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 327.30K | -54.7% | $12.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 327.30K | -54.7% | $12.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | State Street Global Advisors ✦ (passive) | 288.72K | — | $11.32M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 273.35K | +12.2% | $10.72M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 86.97K | -57.5% | $3.41M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passive) | 69.53K | +1.1% | $2.73M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 13.70K | -68.9% | $537,040 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $15.09M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 129.80K shares, $7,547 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 10.00K sh · $640,550
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology